tertiary epilepsy centers. Those who decide on follow-up are likely different from those who do not. Short-term outcome (immediately upon communicating the diagnosis) is better, but there is rapid falloff over months (2) . While communicating the diagnosis of PNES may halt seizures early on for a minority of patients (3) , the majority continue to recur or develop other functional symptoms even though they decrease their health care utilization (4) . Long-term outcome studies are far fewer and have variable results, though one large study showed sustained reduction of anticonvulsant use but poor return to employment and poor psychiatric outcomes (5) . Better understanding of long-term outcomes for PNESs and other FNDs will help to inform treatment for these complex disorders.
Psychogenic syncope (or psychogenic pseudosyncope, PPS), a less common and much less studied cause of loss of consciousness, has similarities and overlap with PNESs and may be more likely be missed as it often presents to cardiologists or internists who are less likely to refer to psychiatrists even when the etiology is unexplained (6) . Until recently, there have been no studies on outcomes in PPS, in part because of the extreme difficulty in gathering a reliable case series. Saal and colleagues (7) were able to gather retrospective data on long-term outcomes for PPS, identifying 57 patients followed over a period of 50 months to 8 years. They required positive features for diagnosis: eyes closed during the attack, high frequency of spells, long duration, and an episode captured Long-Term Follow-Up of Psychogenic Pseudosyncope. Saal OBJECTIVE: To determine the outcome of patients with psychogenic pseudosyncope (PPS) after communication of the diagnosis. METHODS: This was a retrospective cohort study of patients with PPS referred in 2007 to 2015 to a tertiary referral center for syncope. We reviewed patient records and studied attack frequency, factors affecting attack frequency, health care use, and quality of life using a questionnaire. We explored influences on attack freedom and attack frequency in the 6 months before follow-up for age, sex, education level, duration until diagnosis, probability of diagnosis, additional syncope, and acceptance of diagnosis. RESULTS: Forty-seven of 57 patients with PPS could be traced, of whom 35 (74%) participated. Twelve (34%) were attack-free for at least 6 months. The median time from diagnosis to follow-up was 50 months (range 6-103 months). Communicating and explaining the diagnosis resulted in immediate reduction of attack frequency (p = 0.007) from the month before diagnosis (median one attack, range 0-156) to the month after (median one attack, range 0-16). In the 6 months before follow-up, the number of admissions decreased from 19 of 35 to 0 of 35 (p = 0.002). The use of somatic and mental health care shifted toward the latter (p < 0.0001). Quality of life at follow-up (Short Form Health Survey 36) showed lower scores for 7 of 8 domains compared to matched Dutch control values; quality of life was not influenced by attack freedom. CONCLUSIONS: After communication of the diagnosis in PPS, attack frequency decreased and health care use shifted toward mental care. Low quality of life underlines that PPS is a serious condition.
Long-Term Outcomes in Psychogenic Syncope: A Fallout for Neurologists
on tilt testing with continual blood pressure measurements to be considered definite PPS; otherwise they were considered to have probable PPS. They enrolled 35 patients with PPS (33 definite, 2 probable), of whom 57% also had comorbid syncope, a higher percentage than the 10-25% of comorbid epilepsy reported in PNES studies. However, similar to PNES, nearly 70% of participant were women who had a mean age of 36 years at diagnosis and had low quality of life. A clear explanation of the psychological nature of the diagnosis reduced PPS immediately. Whether patients accepted the psychological nature of the disorder did not seem to affect their outcome. Also, at delayed follow-up, one third of participants were still without episodes of PPS.
This study is the first to gather a series of patients with PPS, and their methods are sound. The size of this series is also good. However, there are some limitations to this study. First, similar to other outcomes studies for FNDs, this study is a retrospective and biased sample obtained through referrals to a tertiary center. Second, there is no control group in the study to compare PPS to other FNDs or syncope outcomes. Instead, subjects were compared with normative data on quality-oflife measures. In addition, this study did not utilize a standard treatment. Most importantly though, there are likely a large number of patients with PPS who remain undiagnosed and therefore are not directed to mental health treatment.
Sending patients to subspecialty clinicians based on different somatic symptoms and different practice styles is problematic for patients with FNDs, including PPS, and can readily lead to disintegration of their care. Providers have variable levels of comfort with these patients, and access to knowledgeable and caring providers is inconsistent and may interfere with outcomes. This has not been studied. Many patients are prescribed unhelpful, expensive, and potentially dangerous medications over years and lack continuity of care as they reverberate through the health system circuit without a central clinician. If we begin to insist that one clinician take responsibility as leader of the team of care providers for communicating clearly, treating these patients with dignity and respect, and tracking what happens to them, we are more likely to measure the true results of our interventions and find out what works for patients. We will not be successful if we do not stop the fallout with FNDs.
by Barbara A. Dworetzky, MD
